semaglutide diabetes research GLP-1 receptor agonists can reduce the risk of adverse cardiovascular events in pts with diabetes. Whether the GLP-1 receptor agonist can also reduce cardiovascular risk in pts with overweight or obesity Diabetes Drug Could Help Reduce

That is basically a 27 BMI (body mass index) and a weight-related comorbidity, or a 30 BMI and above. Comorbidities include type 2 diabetes, hypertension, dyslipidemia, heart disease, osteoarthritis, obstructive sleep apnea, kidney disease and non-alcoholic fatty liver disease

The key difference is what the FDA says you can use it for

Low levels of adipocyte markers such peroxisome proliferator-activated receptor (PPAR), TNF-receptor superfamily member 6, GLUT4, and fatty acid-binding protein 4 were observed [165], [166]

In addition, this medication also suppresses gastric acid secretion and promotes satiety, resulting in appetite reduction